Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 1/20 | 0.34 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24573625 | 1.00 | AKT1 (0.34) | AKT1EGFR | |
| SCHEMBL24573423 | 0.93 | AKT1 (0.32) | AKT1EGFR | |
| SCHEMBL30248878 | 0.93 | AKT1 (0.32) | AKT1EGFR | |
| SCHEMBL30248958 | 0.86 | NPBWR1 (0.34) | EGFR | |
| SCHEMBL24573583 | 0.86 | NPBWR1 (0.34) | EGFR | |
| SCHEMBL24573323 | 0.85 | TUBB4A (0.33) | EGFR | |
| SCHEMBL29734232 | 0.85 | TUBB4A (0.33) | EGFR | |
| SCHEMBL24573240 | 0.83 | AKT1 (0.33) | AKT1 | |
| SCHEMBL29735046 | 0.83 | AKT1 (0.33) | AKT1 | |
| SCHEMBL24573300 | 0.83 | ADRA1A (0.32) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | claimed |
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | NOVARTIS AG (CH) | 2025-09-02 | — | — | US | disclosed |
| EP-4267564-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | Novartis AG (CH) | 2023-11-01 | — | — | EP | disclosed |
| CN-116635382-A | Indole derivatives useful for treating cGAS-related disorders | 诺华股份有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | NOVARTIS PHARMA AG (CH) | 2023-03-16 | — | — | US | disclosed |
| WO-2022137085-A1 | INDOLE DERIVATIVES USEFUL IN TREATING CONDITIONS ASSOCIATED WITH CGAS | NOVARTIS AG (CH) | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12404261-B2 | Compounds and compositions for treating conditions associated with cGAS | CGAS, TDP1, IAPP | AKT1 2419/4885EGFR 4104/4885 |
| US-20230085472-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH cGAS | CGAS, TDP1, IAPP | AKT1 2419/4885EGFR 4104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.